Harbin Gloria Pharmaceuticals (002437) — Net Asset Quality Index
Harbin Gloria Pharmaceuticals (002437) has a Net Asset Quality Index of 76.6% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥3.14 Billion minus total liabilities of CN¥735.96 Million yields net assets of CN¥2.41 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check how resilient are Harbin Gloria Pharmaceuticals's assets to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
Harbin Gloria Pharmaceuticals Net Asset Quality Index Over Time (2007–2025)
This chart shows how Harbin Gloria Pharmaceuticals's Net Asset Quality Index has evolved across 19 annual periods from 2007 to 2025. As of March 2026, the index stands at 76.6%, representing net assets of CN¥2.41 Billion against total assets of CN¥3.14 Billion CNY. See how liquid is Harbin Gloria Pharmaceuticals's working capital to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Harbin Gloria Pharmaceuticals (2007–2025)
The table below presents the year-by-year Net Asset Quality Index for Harbin Gloria Pharmaceuticals from 2007 to 2025, covering 19 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see market value of Harbin Gloria Pharmaceuticals.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 73.7% | CN¥2.31 Billion | CN¥3.13 Billion | CN¥825.00 Million | ▲ +3.8 pp |
| 2024 | 69.8% | CN¥1.97 Billion | CN¥2.83 Billion | CN¥852.26 Million | ▲ +15.6 pp |
| 2023 | 54.3% | CN¥1.71 Billion | CN¥3.15 Billion | CN¥1.44 Billion | ▲ +12.4 pp |
| 2022 | 41.8% | CN¥1.70 Billion | CN¥4.07 Billion | CN¥2.37 Billion | ▼ -0.3 pp |
| 2021 | 42.1% | CN¥1.98 Billion | CN¥4.70 Billion | CN¥2.72 Billion | ▼ -0.7 pp |
| 2020 | 42.8% | CN¥1.93 Billion | CN¥4.52 Billion | CN¥2.58 Billion | ▲ +18.0 pp |
| 2019 | 24.8% | CN¥1.59 Billion | CN¥6.41 Billion | CN¥4.82 Billion | ▼ -21.6 pp |
| 2018 | 46.4% | CN¥4.39 Billion | CN¥9.48 Billion | CN¥5.08 Billion | ▼ -0.6 pp |
| 2017 | 46.9% | CN¥4.25 Billion | CN¥9.06 Billion | CN¥4.81 Billion | ▲ +0.2 pp |
| 2016 | 46.7% | CN¥4.05 Billion | CN¥8.67 Billion | CN¥4.62 Billion | ▲ +4.9 pp |
| 2015 | 41.7% | CN¥3.47 Billion | CN¥8.32 Billion | CN¥4.85 Billion | ▼ -21.3 pp |
| 2014 | 63.0% | CN¥3.10 Billion | CN¥4.92 Billion | CN¥1.82 Billion | ▼ -21.2 pp |
| 2013 | 84.2% | CN¥2.48 Billion | CN¥2.94 Billion | CN¥464.60 Million | ▼ -7.8 pp |
| 2012 | 92.1% | CN¥2.36 Billion | CN¥2.56 Billion | CN¥203.79 Million | ▼ -3.0 pp |
| 2011 | 95.0% | CN¥2.20 Billion | CN¥2.31 Billion | CN¥114.91 Million | ▼ -1.6 pp |
| 2010 | 96.6% | CN¥2.12 Billion | CN¥2.19 Billion | CN¥73.73 Million | ▲ +31.7 pp |
| 2009 | 65.0% | CN¥287.53 Million | CN¥442.48 Million | CN¥154.95 Million | ▼ -4.5 pp |
| 2008 | 69.5% | CN¥194.04 Million | CN¥279.21 Million | CN¥85.17 Million | ▲ +5.3 pp |
| 2007 | 64.2% | CN¥138.36 Million | CN¥215.51 Million | CN¥77.15 Million | — |